DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sevirumab
Sevirumab
Inclusion and Exclusion Criteria for Each Key Question
(12) United States Patent (10) Patent No.: US 9.468,689 B2 Zeng Et Al
WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens
Modifications to the Harmonized Tariff Schedule of the United States To
Pharmaceutical Appendix to the Tariff Schedule 2
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
(INN) for Biological and Biotechnological Substances
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
Antibody Therapies for the Prevention and Treatment of Viral Infections
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
(12) United States Patent (10) Patent No.: US 9,677,055 B2 Jones Et Al
Ep 2966085 A1
Oo-()-No,O Ra50
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Top View
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
WO 2U11/1 7921 a L
Wo 2010/095940 A2
Antibody-Drug Analogues
Assessment of the Evolution of Cancer Treatment Therapies
(12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
La Merie Publishing
Customs Tariff - Schedule Xxi - 1
Tim Malawi Mai Multe
Embase 1988 to 2014 Week 36, Ovid MEDLINE(R) In-Process
Vaccine Monoclonal Antibody-Based Therapies for Microbial Diseases
Harmonized Tariff Schedule of the United States (2006) (Rev
Determination of the Starting Dose in the First-In- Human Clinical Trials with Monoclonal Antibodies: a Systematic Review of Papers Published Between 1990 and 2013
(12) Patent Application Publication (10) Pub. No.: US 2015/0010548 A1 Jesek Et Al
(INN) for Biological and Biotechnological Substances
Harmonized Tariff Schedule of the United States (2003) -- Supplement 1 Annotated for Statistical Reporting Purposes
Assessment of the Evolution of Cancer Treatment Therapies
WO 2013/120629 Al 22 August 2013 (22.08.2013) P O P C T
Supplemental Table 1: Inclusion and Exclusion Criteria
WHO Drug Information Vol. 05, No. 4, 1991
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri